BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26511478)

  • 1. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
    Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N
    Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment.
    Cañas-Ventura A; Márquez L; Ricart E; Domènech E; Gisbert JP; García-Sanchez V; Marín-Jiménez I; Rodriguez-Moranta F; Gomollón F; Calvet X; Merino O; Garcia-Planella E; Vázquez-Romero N; Esteve M; Iborra M; Gutiérrez A; Vera M; Andreu M;
    J Crohns Colitis; 2014 Oct; 8(10):1287-93. PubMed ID: 24726696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
    Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
    Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
    Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
    Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M;
    Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin as a prognostic marker for ulcerative colitis.
    Khan N; Patel D; Shah Y; Trivedi C; Yang YX
    World J Gastroenterol; 2017 Dec; 23(45):8008-8016. PubMed ID: 29259376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
    Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis.
    Yamamoto S; Nakase H; Matsuura M; Masuda S; Inui K; Chiba T
    J Clin Gastroenterol; 2011 Jul; 45(6):526-30. PubMed ID: 21336140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study.
    Prieux-Klotz C; Nahon S; Amiot A; Sinayoko L; Galéano-Cassaz C; Chaussade S; Coriat R; Lahmek P; Abitbol V
    Dig Dis Sci; 2017 Feb; 62(2):473-480. PubMed ID: 27853898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
    Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
    World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012).
    Golovics PA; Lakatos L; Mandel MD; Lovasz BD; Vegh Z; Kurti Z; Szita I; Kiss LS; Balogh M; Pandur T; Lakatos PL
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):287-92. PubMed ID: 26405700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
    Yarur AJ; Gondal B; Hirsch A; Christensen B; Cohen RD; Rubin DT
    J Clin Gastroenterol; 2018 Jul; 52(6):537-544. PubMed ID: 28723860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic features of Crohn's disease associated with failure of medical treatment.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
    O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.